Neoadjuvant chemotherapy should be reserved for those in whom optimal primary cytoreductive surgery is not feasible.

**Abstracts**

**2022-RA-792-ESGO** OUTCOMES FOLLOWING STEREOTACTIC RADIOTHERAPY FOR BRAIN METASTASIS IN OVARIAN CANCER PATIENTS

1Shira Peleg Hasson, 2Nicola Rosenfelder, 3Martin Brewet, 4Angela George, 5Liam Walsh, 6Susana Banejee, 7Gynaec Unit, The Royal Marsden Foundation Trust, London, UK; 8Neuro-Oncology Unit, The Royal Marsden Foundation Trust, London, UK; 9Radiotherapy department, The Royal Marsden Foundation Trust, London, UK

**Methodology**

Patients with primary OC were included before start of treatment. QoL was assessed by the cancer-specific FACT-0.012) were independent predictors of overall survival.

In a univariate analysis, high serum NLR, malignant ascitic NLR were associated with shorter overall survival (p < 0.001, p < 0.001, respectively); moreover, age, Eastern Cooperative Oncology Group performance status (ECOG PS), histology, stage, hemoglobin level, albumin level, and calcium level were significant prognostic factors. A multivariable analysis confirmed that ECOG PS (p < 0.001), histology (p = 0.001), serum NLR (p = 0.007) and malignant ascitic NLR (p = 0.012) were independent predictors of overall survival.

**Conclusion**

Our findings showed that an elevated preoperative NLR in serum and malignant ascites were associated with poor clinical outcome in ovarian cancer patients. Although further studies are required to generalize our results, this information will benefit clinicians and patients in determining the most appropriate therapy for patients with malignant ascites.

**2022-RA-798-ESGO** DIAGNOSIS OF FIRST RELAPSE AND ITS IMPACT ON QUALITY OF LIFE IN PATIENTS WITH ADVANCED OVARIAN CANCER (AGO- OVAR 19/II)

1Philipp Hartler, 2Beyhan Ataseven, 3Alexander Burgers, 4Alexander Reuss, 5Stefan Krommoss, 6Jalid Sehouli, 7Björn Lampe, 8Barbara Schmalfeldt, 9Pauline Wimberger, 10Ralf Wittler, 11Paul Buderdath, 12Ulve Henwig, 13Holger Bronner, 14Günter Emons, 15Maximilian Klar, 16Annette Hasenburg, 17Nikolaus de Gregorio, 18Felix Hiltrop, 19Andreas du Bois, 20Sven Mahner, 21Ev Klinik, Essen, Germany; 22Klinikum rechts der Isar, Munich, Germany; 23Klinikum der Ludwig Maximilian University of Munich, Munich, Germany; 24UKE Hamburg, Hamburg, Germany; 25University Hospital Tubingen, Tubingen, Germany; 26Campus Virchow, Charité, Berlin, Germany; 27Kaiserwerther Diakonie, Düsseldorf, Germany; 28UKE Hamburg, Hamburg, Germany; 29University Hospital, TU Dresden, Dresden, Germany; 30University Hospital Münster, Münster, Germany; 31University Hospital Essen, Essen, Germany; 32Albertinen Krankenhaus Hamburg, Hamburg, Germany; 33Klinikum rechts der isar, Munich, Germany; 34University Hospital Göttingen, Göttingen, Germany; 35University Hospital, Faculty of Medicine, Freiburg, Germany; 36University Hospital Mainz, Mainz, Germany; 37University Hospital Ulm, Ulm, Germany; 38Mammazentrum HH am Krankenhaus Jerusalem, Hamburg, Germany

**Methodology**

We retrospectively reviewed all of the patients who were diagnosed with advanced epithelial ovarian cancer and who presented with ascites. To maintain the quality of the study, only 92 patients with malignant cells in the ascites were included. Patients with clinically active infection in the time of paracentesis is excluded. If multiple times of paracentesis was done, we used initial result. Curves of DFS and OS were calculated using the Kaplan-Meier method, and univariate and multivariate analyses of various prognostic factors were performed using a Cox proportional hazard regression model.

**Results**

In a univariate analysis, high serum NLR, malignant ascitic NLR were associated with shorter overall survival (p < 0.001, p < 0.001, respectively); moreover, age, Eastern Cooperative Oncology Group performance status (ECOG PS), histology, stage, hemoglobin level, albumin level, and calcium level were significant prognostic factors. A multivariable analysis confirmed that ECOG PS (p < 0.001), histology (p = 0.001), serum NLR (p = 0.007) and malignant ascitic NLR (p = 0.012) were independent predictors of overall survival.

**Conclusion**

Our findings showed that an elevated preoperative NLR in serum and malignant ascites were associated with poor clinical outcome in ovarian cancer patients. Although further studies are required to generalize our results, this information will benefit clinicians and patients in determining the most appropriate therapy for patients with malignant ascites.

**Introduction/Background**

Neoadjuvant chemotherapy should be reserved for those in whom optimal primary cytoreductive surgery is not feasible.

**Methodology**

We retrospectively reviewed all of the patients who were diagnosed with advanced epithelial ovarian cancer and who presented with ascites. To maintain the quality of the study, only 92 patients with malignant cells in the ascites were included. Patients with clinically active infection in the time of paracentesis is excluded. If multiple times of paracentesis was done, we used initial result. Curves of DFS and OS were calculated using the Kaplan-Meier method, and univariate and multivariate analyses of various prognostic factors were performed using a Cox proportional hazard regression model.

**Results**

In a univariate analysis, high serum NLR, malignant ascitic NLR were associated with shorter overall survival (p < 0.001, p < 0.001, respectively); moreover, age, Eastern Cooperative Oncology Group performance status (ECOG PS), histology, stage, hemoglobin level, albumin level, and calcium level were significant prognostic factors. A multivariable analysis confirmed that ECOG PS (p < 0.001), histology (p = 0.001), serum NLR (p = 0.007) and malignant ascitic NLR (p = 0.012) were independent predictors of overall survival.

**Conclusion**

Our findings showed that an elevated preoperative NLR in serum and malignant ascites were associated with poor clinical outcome in ovarian cancer patients. Although further studies are required to generalize our results, this information will benefit clinicians and patients in determining the most appropriate therapy for patients with malignant ascites.
based pre- and post-recurrence means and p-values for the difference in means.

Results 269 of 486 enrolled patients had a PFS event resulting in a median PFS of 20.3 months. This analysis includes QoL-evaluable 186 patients. Median age was 62.5 years (range 31 – 90). The number of evaluable answers for each domain ranged between 166 and 172 before recurrence and 135 and 137 after recurrence. Global QoL decreased from 61.4 to 48.4 points (p<0.001) with the diagnosis of recurrence. The following scales showed a deterioration of at least 10 points: Social functioning (65.7 -> 52.6), fatigue (44.5 -> 55.8), appetite loss (22.5 -> 33.4), emotional functioning (65.2 -> 54.9), role functioning (56.5 -> 46.4); (all p<0.001). EQ-SD 3L visual analogue scale showed a deterioration from 66.4 to 55.0 (p<0.001).

Conclusion The event of first relapse is associated with a significant and clinically relevant deterioration of global QoL including several subscales. Therefore, prolongation of PFS preserves QoL, which supports the role of PFS as meaningful primary endpoint in ovarian cancer trials.

Introduction/Background The time window prior to debulking surgery offers a unique opportunity to directly study the response of treatment-naïve epithelial ovarian cancer (EOC) to targeted therapies alone or in combinations and to obtain serial tissue and liquid biopsies to study clinically useful predictive biomarkers, e.g. for poly-ADP-ribose-polymerase (PARP) inhibitors and/or immune checkpoint inhibitors. As distinct from a neoadjuvant concept, the observed effect will not be obscured by highly effective platinum-based chemotherapy.

Methodology This proof-of-concept, non-randomized, open-label, phase II trial of Olaparib given alone or in combination with Durvalumab prior to primary debulking surgery in histologically proven high-grade epithelial ovarian cancer (OC) is the most lethal gynaecological cancer for which long-term survival is conditioned by surgery and chemotherapy. Striking a balance between this comprehensive treatment combination and the patient population, with a substantial number of older women, poses a continuous challenge. Older patients with EOC repeatedly demonstrate poor survival compared to younger. Yet, age itself cannot explain the survival gap. We aimed to explore differences between older and younger patients regarding surgical complexity, chemotherapy management, and treatment delays in Denmark.

Methodology We included a nationwide cohort of patients diagnosed with EOC from 2013 to 2018. We described surgical modality (primary, interval, or no debulking surgery). We assessed the cancer-specific survival. For patients with advanced-stage disease, 52% of the older and 25% of the younger patients underwent neither primary debulking surgery (PDS) nor interval debulking surgery (IDS). For patients that did undergo PDS or IDS, older patients had less extensive surgery and were more likely to have residual disease after surgery than younger patients. Furthermore, chemotherapy was given less frequently to older patients. Yet, we found no differences across age cohorts regarding treatment delays according to national cancer patient pathways. Two-year cancer-specific survival differed significantly between age groups favouring the younger patients, regardless of whether patients underwent curatively intended treatment or not.

Conclusion Our study demonstrates that older patients receive less active surgical and oncological treatment than younger patients, resulting in lower cancer-specific survival. Treatment delays are not more common in older patients than in younger patients.

---

**Abstracts**

**2022-RA-800-ESGO**

**AGO-OVAR 27: WINDOW-OF-OPPORTUNITY PROOF-OF-CONCEPT, NON-RANDOMIZED, OPEN-LABEL PHASE II TRIAL OF OLAPARIB GIVEN ALONE OR IN COMBINATION WITH DURVALUMAB PRIOR TO PRIMARY DEBULking SURGERY IN HISTOLOGICALLY PROVEN HIGH-GRADE EPITHELIAL OVARIAN CANCER**

1 Frederik Marmé, 2 Florian Heitz, 3 Philipp Harter, 4 Alexander Reuss, 5 Friederike Kipkeev, 6 Pauline Winkinger, 7 Huiger Bronger, 8 Andreas du Bais, 9 Jadid Sehouli, 10 Felix Hilpert. 1 AGO Study Group, Mannheim, Germany; 2 AGO Study Group, Essen, Germany; 3 AGO and Coordinating Center for Clinical Trials, Marburg, Germany; 4 AGO Study Group, Dresden, Germany; 5 AGO Study Group, Munich, Germany; 6 AGO Study Group, Berlin, Germany; 7 AGO Study Group, Hamburg, Germany.

**Introduction/Background** The time window prior to debulking surgery offers a unique opportunity to directly study the response of treatment-naïve epithelial ovarian cancer (EOC) to targeted therapies alone or in combinations and to obtain serial tissue and liquid biopsies to study clinically useful predictive biomarkers, e.g. for poly-ADP-ribose-polymerase (PARP) inhibitors and/or immune checkpoint inhibitors. As distinct from a neoadjuvant concept, the observed effect will not be obscured by highly effective platinum-based chemotherapy.

**Methodology** This proof-of-concept, non-randomized, open-label, phase II trial of Olaparib given alone (cohort A) or in combination with Durvalumab (cohort B) prior to primary debulking surgery in histologically proven high-grade EOC evaluates the feasibility of the window-of-opportunity (WoO) procedure. Patients with suspected advanced high-grade EOC scheduled to undergo diagnostic laparoscopy for histologic confirmation will be registered into the trial. Only those deemed candidates for primary debulking surgery and with histologically confirmed diagnosis of high-grade EOC, fulfilling all other inclusion criteria, will then be included in the WoO treatment phase. WoO treatment phase will be followed by primary debulking surgery and standard-of-care platinum-based first-line chemotherapy and maintenance therapy. Fresh-frozen and corresponding Formalin-fixed-paraffin-embedded (FFPE) tumor samples will be obtained for translational research at laparoscopy and primary debulking surgery. Plasma samples for circulating tumor DNA (ctDNA) analysis and plasma/serum samples for further translational research analyses will be obtained during all phases of the study at defined time points. It is planned to enroll 30 patients per cohort. After completion of cohort A, a trial steering committee will review safety and feasibility prior to starting cohort B. Further information: NCT04644289.

**Results** The first patient has been enrolled recently.

**Conclusion** This concept might open the possibility to investigate the predictive value of biomarkers for benefit from PARP and immune-checkpoint inhibitors in the treatment of EOC.

**Sponsor:** AGO Study Group. Financial support and drug supply: AstraZeneca.

---

**2022-RA-805-ESGO**

**IMPACT OF SURGERY AND CHEMOTHERAPY TIMING ON OUTCOMES IN OLDER VERSUS YOUNGER EPITHELIAL OVARIAN CANCER PATIENTS: A NATIONWIDE DANISH COHORT STUDY**

1 Anne Weng Ekmann-Gade, 2 Tine Henrichsen Schnack, 3 Lene Seibæk, 4 Mette Calundann Nørr, 5 Claus Høgdall. 1 Department of Gynecology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; 2 Department of Gynecology, Odense University Hospital, Odense, Denmark; 3 Department of Gynecology, Aarhus University Hospital, Aarhus, Denmark; 4 Department of Gynecology and Obstetrics, Nordsjællands Hospital, Hillerød, Denmark.

**Introduction/Background** Epithelial ovarian cancer (EOC) is the most lethal gynaecological cancer for which long-term survival is conditioned by surgery and chemotherapy. Striking a balance between this comprehensive treatment combination and the patient population, with a substantial number of older women, poses a continuous challenge. Older patients with EOC repeatedly demonstrate poor survival compared to younger. Yet, age itself cannot explain the survival gap. We aimed to explore differences between older and younger patients regarding surgical complexity, chemotherapy management, and treatment delays in Denmark.

**Methodology** We included a nationwide cohort of patients diagnosed with EOC from 2013 to 2018. We described surgical complexity and outcomes, the extent of chemotherapy and treatment delays stratified by age (< 70 and ≥ 70 years), and surgical modality (primary, interval, or no debulking surgery). Finally, we assessed the cancer-specific survival.

**Results** We included 2,946 patients in total. For patients with advanced-stage disease, 52% of the older and 25% of the younger patients underwent neither primary debulking surgery (PDS) nor interval debulking surgery (IDS). For patients that did undergo PDS or IDS, older patients had less extensive surgery and were more likely to have residual disease after surgery than younger patients. Furthermore, chemotherapy was given less frequently to older patients. Yet, we found no differences across age cohorts regarding treatment delays according to national cancer patient pathways. Two-year cancer-specific survival differed significantly between age groups favouring the younger patients, regardless of whether patients underwent curatively intended treatment or not.

**Conclusion** Our study demonstrates that older patients receive less active surgical and oncological treatment than younger patients, resulting in lower cancer-specific survival. Treatment delays are not more common in older patients than in younger patients.

---

**Int J Gynecol Cancer 2022;32(Suppl 2):A1–A504**